Rocket Pharmaceuticals (RCKT) Asset Writedowns and Impairment (2014 - 2020)

Rocket Pharmaceuticals (RCKT) reported Asset Writedowns and Impairment of -$1000.0 for Q2 2020, down 101.59% sequentially from $63000.0 in Q1 2020.

Rocket Pharmaceuticals (RCKT) Asset Writedowns and Impairment (2014 - 2020) Analysis & Trends

Rocket Pharmaceuticals (RCKT) has 4 years of Asset Writedowns and Impairment data on file, last reported at -$1000.0 in Q2 2020.

For the quarter ending Q2 2020, Asset Writedowns and Impairment changed N/A year-over-year to -$1000.0; the trailing twelve-month figure through Dec 2023 stood at -$1000.0 (down 101.61% YoY), and the FY2025 full-year result was $262000.0, changed N/A from the prior year.
Asset Writedowns and Impairment slipped to -$1000.0 in Q2 2020, from $63000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $63000.0 in Q1 2020 to a low of -$1000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Rocket Pharmaceuticals	367.24 Mn	367.24 Mn	-

Download Data